SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
KYTHERA BIOPHARMACEUTICALS INC
(NQNM:KYTH Last Sale: 34.98 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (KYTH : $34.98)
$607 million Market Cap at September 12, 2013
Biomedics SubIndustry up .00% / Health Industry up .00% Today
Research Report Earnings Snapshot - Last 11/10/18
Fact Sheet
Financial Statements
Peer Comparison
Annual Reports


Focus is on the facial aesthetics market. Product candidate, ATX-101, is a potential first-in-class, injectable drug in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable "double chin." ATX-101 is a proprietary synthetic formulation of sodium deoxycholate, a component of human bile. IPO at $16 October 11, 2012. Raised $70.4 million, selling 4.4 million shares, 25% of the outstanding. Lead Manager: J.P. Morgan.
Historical Charts    Technical Analysis
No Historical Data available for KYTH

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common KYTH $34.98 $ 0 $32.19 $35.8 235,970 $14.07 $35.8 17,366
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $607,450

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex